Skip Nav

HIV/AIDS Clinical Trials

Recruiting Status Legend

Studies Seeking Participants

Recruiting
Not yet recruiting
Available for expanded access

Studies Not Seeking Participants

Active, not recruiting
Completed
Terminated
Suspended
Withdrawn
Enrolling by invitation
Temporarily not available for expanded access
No longer available for expanded access
Approved for marketing

Clinical Trial Search Results

13 studies were found about ( Complera OR emtricitabine AND rilpivirine AND tenofovir disoproxil fumarate )

Assessing Short and Long Term Compliance With Caloric Intake in HIV Positive Women Taking Complera

Condition: HIV-1 Infection

NCT ID: NCT01701895

Recruiting

Study to Evaluate the Safety and Efficacy of a Single Tablet Regimen of Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate Compared With a Single Tablet Regimen of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naïve Adults.

Condition: HIV-1 Infection

NCT ID: NCT01309243

Active, not recruiting

Study to Evaluate Switching From a Regimen Consisting of the Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate Single-Tablet Regimen (STR) to the Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate STR

Condition: HIV-1 Infection

NCT ID: NCT01286740

Completed

Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor (PI) and Two Nucleoside Reverse Transcriptase Inhibitors (NRTIs) to a Fixed-dose Tablet Containing Emtricitabine/Rilpivirine/Tenofovir DF

Condition: HIV-1 Infection

NCT ID: NCT01252940

Active, not recruiting

A Study to Compare Efficacy in Terms of Plasma Human Immunodeficiency Virus-Type 1 (HIV-1) Ribonucleic Acid (RNA) Between 2 Fixed Dose Combinations After a Switch in Fully Suppressed Patients

Condition: Human Immunodeficiency Virus-type 1 Infection

NCT ID: NCT01709084

Not yet recruiting

FTC/RPV/TDF on T-Cell Activation, CD4 Cell Count, Inflammatory Biomarkers and Viral Reservoir

Condition: HIV-1 Infection

NCT ID: NCT01777997

Not yet recruiting

TMC278-TiDP6-C209: A Clinical Trial in Treatment Naive HIV-1 Patients Comparing TMC278 to Efavirenz in Combination With Tenofovir + Emtricitabine.

Condition: HIV Infections; HIV-1; Human Immunodeficiency Virus Type 1

NCT ID: NCT00540449

Completed

Safety, Tolerability,and Adherence to Co-formulated Tenofovir-emtricitabine-rilpivirine Used as HIV Nonoccupational Post-exposure Prophylaxis in Men Who Have Sex With Men.

Condition: HIV Nonoccupational Post-exposure Prophylaxis in Men Who Have Sex With Men

NCT ID: NCT01715636

Not yet recruiting

Dose Ranging Study of GSK1265744 Plus Nucleoside Reverse Transcriptase Inhibitors for Induction of Human Immunodeficiency Virus-1 (HIV-1) Virologic Suppression Followed by Virologic Suppression Maintenance by GSK1265744 Plus Rilpivirine

Condition: Infection, Human Immunodeficiency Virus

NCT ID: NCT01641809

Active, not recruiting

A Pilot Study to Assess the Feasibility of Switching, Individuals Receiving Atripla With Continuing Central Nervous System (CNS) Toxicity, to a Fixed Dose Combination of Tenofovir/Emtricitabine/Rilpivirine

Condition: HIV

NCT ID: NCT01701882

Active, not recruiting

A Study to Evaluate the Pharmacokinetics, Safety, Tolerability, and Antiviral Efficacy of TMC278 in Human Immunodeficiency Virus Infected Adolescents

Condition: Human Immuno Deficiency (HIV) Infections

NCT ID: NCT00799864

Recruiting

Pharmacokinetics of Tenofovir and Tenofovir-diphosphate, Emtricitabine and Emtricitabine-triphosphate, and Rilpivirine Once Daily Over 14 Days Following Drug Intake Cessation in Healthy Volunteers

Condition: HIV

NCT ID: NCT01796431

Recruiting

Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Non-nucleoside Reverse Transcriptase Inhibitor Plus Emtricitabine and Tenofovir DF to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients

Condition: Acquired Immunodeficiency Syndrome; HIV Infections

NCT ID: NCT01495702

Active, not recruiting